- Home
- CAPR vs TVA Comparison
CAPR vs TVA Comparison
Compare CAPR & TVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- TVA
- Stock Information
- Founded
- CAPR 2005
- TVA 2024
- Country
- CAPR United States
- TVA United States
- Employees
- CAPR N/A
- TVA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- TVA
- Sector
- CAPR Health Care
- TVA
- Exchange
- CAPR Nasdaq
- TVA Nasdaq
- Market Cap
- CAPR 324.6M
- TVA 303.4M
- IPO Year
- CAPR N/A
- TVA 2025
- Fundamental
- Price
- CAPR $6.28
- TVA $10.13
- Analyst Decision
- CAPR Strong Buy
- TVA
- Analyst Count
- CAPR 8
- TVA 0
- Target Price
- CAPR $24.75
- TVA N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- TVA 32.0
- Earning Date
- CAPR 08-11-2025
- TVA 01-01-0001
- Dividend Yield
- CAPR N/A
- TVA N/A
- EPS Growth
- CAPR N/A
- TVA N/A
- EPS
- CAPR N/A
- TVA N/A
- Revenue
- CAPR $13,392,150.00
- TVA N/A
- Revenue This Year
- CAPR N/A
- TVA N/A
- Revenue Next Year
- CAPR $6,061.53
- TVA N/A
- P/E Ratio
- CAPR N/A
- TVA N/A
- Revenue Growth
- CAPR N/A
- TVA N/A
- 52 Week Low
- CAPR $3.98
- TVA $9.99
- 52 Week High
- CAPR $23.40
- TVA $10.34
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- TVA N/A
- Support Level
- CAPR $6.17
- TVA N/A
- Resistance Level
- CAPR $7.30
- TVA N/A
- Average True Range (ATR)
- CAPR 0.43
- TVA 0.00
- MACD
- CAPR -0.11
- TVA 0.00
- Stochastic Oscillator
- CAPR 4.53
- TVA 0.00
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About TVA Texas Ventures Acquisition III Corp Class A Ordinary Share
Texas Ventures Acquisition III Corp is a blank check company.